
About the Inherited Retinal Disease Session
Inherited Retinal Diseases (IRDs) form a complex array of genetic disorders impacting the retina, gradually diminishing vision. Conditions like retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease arise from genetic mutations, often surfacing in childhood or early adulthood and presenting with varying severity and progression. These diseases stem from genetic anomalies disrupting vital retinal functions, such as phototransduction or retinal development. Symptoms include night blindness, peripheral vision loss, and, in later stages, central vision impairment. Though currently lacking a cure, ongoing research into gene therapy, stem cell therapy, and retinal prosthetics sparks optimism for future treatments. Timely genetic testing aids in tailored management plans and facilitates participation in clinical trials, offering a glimmer of hope for enhanced outcomes in the management of these intricate conditions.
Topics Covered in Inherited Retinal Disease
Retinitis Pigmentosa
Leber Congenital Amaurosis
Stargardt Disease
Molecular Genetic Testing
RPE65 Gene Therapy
Retinal Prosthetics & Stem Cells
Featured Speakers — Inherited Retinal Disease 2027


Recent Research Presented at Inherited Retinal Disease Sessions
From bench to bedside: Gene therapy for inherited retinal diseases — current evidence, emerging therapies and the global challenge of equitable access
Background: Inherited Retinal Diseases (IRDs) are a clinically and genetically heterogeneous group of conditions causing progressive visual impairment, affecting approximately 5.5 million people…
Quality of life in inherited retinal dystrophies
Inherited retinal dystrophies (IRDs) are a leading cause of visual impairment in people aged 15–45 years, affecting an estimated 5.5 million people worldwide, predominantly through retinitis…
Related Scientific Sessions at IOC 2027
Why Attend the Inherited Retinal Disease Conference 2027
Earn CPD Credit
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Present Your Research
Oral and poster slots for original Inherited Retinal Disease work, reviewed by the scientific committee.
Network Globally
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Publish & Get Indexed
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Learn from Keynotes
Plenary lectures from leading voices shaping Inherited Retinal Disease research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join IOC 2027 for the Inherited Retinal Disease track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Inherited Retinal Disease Conference 2027 — FAQs
What is the Inherited Retinal Disease track at IOC 2027?
The Inherited Retinal Disease track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Inherited Retinal Disease. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Inherited Retinal Disease sessions?
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Inherited Retinal Disease are all welcome — whether presenting or attending.
Can I present my research in the Inherited Retinal Disease track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Inherited Retinal Disease sessions?
Yes. IOC 2027 is a hybrid conference — attend the Inherited Retinal Disease track in person in Singapore or join live online, with on-demand access afterward.
Join the IOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
